14 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
expenses; the costs of laboratory supplies and acquiring materials for preclinical studies and clinical trials; the costs associated with wind down … and other current liabilities $ 20,630 $ 19,769 As of December 31, 2023 there were $3.1 million of costs related to wind down activities for CFT8634
8-K
EX-99.1
CCCC
C4 Therapeutics Inc
1 Nov 23
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
7:18am
with CFT8634 as a single agent. No additional patients will be enrolled in the CFT8634 Phase 1 trial and wind down activities are expected to be complete
8-K
EX-10.1
35xpxbpt
30 May 23
Entry into a Material Definitive Agreement
7:30am
S-1
EX-10.12
gn9i7tbbv911pjn4
10 Sep 20
IPO registration
5:26pm
S-1
EX-3.1
xe94w
10 Sep 20
IPO registration
5:26pm
S-1
EX-10.11
mjc7rj7 3x2xnh6iwsk
10 Sep 20
IPO registration
5:26pm
S-1
EX-10.13
0rk 88xi200xbq
10 Sep 20
IPO registration
5:26pm
DRS
EX-10.7
kzsv4e4x e5i
6 Aug 20
Draft registration statement
12:00am
DRS
EX-10.8
el00em3ki 4dc5xxaim
6 Aug 20
Draft registration statement
12:00am
DRS
EX-10.6
azkvn05
6 Aug 20
Draft registration statement
12:00am
DRS
EX-3.1
gfd gpvizz6p
6 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next